TY - JOUR
T1 - Evaluation of caspofungin and amphotericin B deoxycholate against Candida albicans biofilms in an experimental intravascular catheter infection model
AU - Shuford, Jennifer A.
AU - Rouse, Mark S.
AU - Piper, Kerryl E.
AU - Steckelberg, James M.
AU - Patel, Robin
N1 - Funding Information:
Received 26 January 2006; accepted 18 April 2006; electronically published 28 July 2006. Presented in part: 5th International Symposium on Antimicrobial Agents and Resistance, 27–29 April 2005, Seoul, Korea (abstract MB04). Potential conflicts of interest: none reported. Financial support: Mayo Foundation; Pfizer, Inc. Reprints or correspondence: Dr. Robin Patel, Div. of Infectious Diseases, Dept. of Medicine, Mayo Clinic College of Medicine, 200 First St. SW, Rochester, MN 55905 (patel.robin@ mayo.edu).
PY - 2006/9/1
Y1 - 2006/9/1
N2 - Candida albicans biofilms complicate the treatment of infected implanted intravascular devices because of decreased antifungal susceptibility. In our investigation, 48 rabbits with experimental central venous catheter C. albicans infection were equally allocated to a control arm or to receive amphotericin B deoxycholate or caspofungin treatment while undergoing systemic and intraluminal lock therapy for 7 days. C. albicans was cultured from catheters from all control rabbits, from 3 that received amphotericin B, and from 0 that received caspofungin. Differences in colony counts were detected between the control and amphotericin (P<.001) and control and caspofungin (P<.001) arms. Caspofungin may be useful in the treatment of C. albicans biofilm-associated intravascular catheter infections, which warrants further study.
AB - Candida albicans biofilms complicate the treatment of infected implanted intravascular devices because of decreased antifungal susceptibility. In our investigation, 48 rabbits with experimental central venous catheter C. albicans infection were equally allocated to a control arm or to receive amphotericin B deoxycholate or caspofungin treatment while undergoing systemic and intraluminal lock therapy for 7 days. C. albicans was cultured from catheters from all control rabbits, from 3 that received amphotericin B, and from 0 that received caspofungin. Differences in colony counts were detected between the control and amphotericin (P<.001) and control and caspofungin (P<.001) arms. Caspofungin may be useful in the treatment of C. albicans biofilm-associated intravascular catheter infections, which warrants further study.
UR - http://www.scopus.com/inward/record.url?scp=33748035709&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748035709&partnerID=8YFLogxK
U2 - 10.1086/506452
DO - 10.1086/506452
M3 - Article
C2 - 16897672
AN - SCOPUS:33748035709
VL - 194
SP - 710
EP - 713
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 5
ER -